FDA Advisors: Reject Secondary-Prevention Ezetimibe IndicationFDA Advisors: Reject Secondary-Prevention Ezetimibe Indication

UPDATED // Noting that the secondary-prevention IMPROVE-IT trial's results weren't "clinically substantial," the panel also voiced concerns with hemorrhagic stroke risk and missing study data. Heartwire from Medscape
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news